Ranbaxy & Lilly: Flexibility in Building a Generics Business
Executive Summary
Through Ranbaxy, the joint venture can provide its own raw materials and access highly efficient, low-cost manufacturing and development operations. Lilly contributes sales, marketing and regulatory know-how in the US and other Western markets.
You may also be interested in...
Savoring Sabex: Sandoz' Play in Injectable Generics
Sandoz, the generics unit of Novartis, is buying Sabex, a Canadian maker of injectable generics for $565 million cash, marking its entree into an attractive sector of generics and also the Canadian generics market. The 6X sales multiple aimed to dissuade Sabex owners from shopping for another buyer. Novartis is the only big pharma company to succeed in generics. Its play is opportunistic, but a secondary effect is a free-market response to pressure on big pharma to make drugs more affordable.
Pfizer v. Reddy: Drug Patents Under Fire
Generic firms are attacking drug patents--even before they expire--with increasingly clever legal strategies. And it looks like the FDA may be helping them do it.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.